Prestige Consumer Healthcare (PBH) Beats Q2 Earnings and Revenue Estimates

Core Insights - Prestige Consumer Healthcare (PBH) reported quarterly earnings of $1.07 per share, exceeding the Zacks Consensus Estimate of $0.97 per share, but down from $1.09 per share a year ago, indicating an earnings surprise of +10.31% [1] - The company generated revenues of $274.11 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.87%, although this is a decrease from $283.79 million in the same quarter last year [2] - Prestige Consumer Healthcare has underperformed the market, with shares down approximately 23.4% year-to-date compared to the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.23 on revenues of $294.9 million, and for the current fiscal year, it is $4.51 on revenues of $1.1 billion [7] - The estimate revisions trend for Prestige Consumer Healthcare was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which Prestige Consumer Healthcare belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]